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A B S T R A C T
Pulmonary-artery-hypertension (PAH) is a life-threatening and highly invalidating chronic disorder. Chronic
oxidation contributes to lung damage and disease progression. Peroxiredoxin-2 (Prx2) is a typical 2-cysteine
(Cys) peroxiredoxin but its role on lung homeostasis is yet to be fully deﬁned. Here, we showed that Prx2-/- mice
displayed chronic lung inﬂammatory disease associated with (i) abnormal pulmonary vascular dysfunction; and
(ii) increased markers of extracellular-matrix remodeling. Hypoxia was used to induce PAH. We focused on the
early phase PAH to dissect the role of Prx2 in generation of PAH. Hypoxic Prx2-/-mice showed (i) ampliﬁed
inﬂammatory response combined with cytokine storm; (ii) vascular activation and dysfunction; (iii) increased
PDGF-B lung levels, as marker of extracellular-matrix deposition and remodeling; and (iv) ER stress with acti-
vation of UPR system and autophagy. Rescue experiments with in vivo the administration of fused-recombinant-
PEP-Prx2 show a reduction in pulmonary inﬂammatory vasculopathy and in ER stress with down-regulation of
autophagy. Thus, we propose Prx2 plays a pivotal role in the early stage of PAH as multimodal cytoprotector,
targeting oxidation, inﬂammatory vasculopathy and ER stress with inhibition of autophagy. Collectively, our
data indicate that Prx2 is able to interrupt the hypoxia induced vicious cycle involving oxidation-inﬂammation-
autophagy in the pathogenesis of PAH.
1. Introduction
Pulmonary artery hypertension (PAH) is a life threatening highly
invalidating chronic disorder [1–3]. Although in the last decade
progresses have been made in the identiﬁcations of factors involved in
its pathogenesis, much still remains to be investigated in the me-
chanism involved in the early stage of PAH [3–5]. Regardless of the
initial event, the combination of chronic inﬂammation and chronic
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hypoxia promote a high pro-oxidant environment, mediating disease
progression [1,2,4,6,7].
In this scenario, eﬃcient catabolic pathways to either buildup
misfolded/unfolded proteins or to clear intracellular damaged proteins
are required [8–11]. Studies in diﬀerent models of PAH have shown
that cellular response to face the accumulation of damaged proteins is
mainly through endoplasmic reticulum (ER) stress followed by the ac-
tivation of autophagy to clear damaged proteins and to reduce ER stress
[10,12,13]. Indeed, classic chaperones such as heat shock protein 90
and 70 (HSP) are upregulated in PAH, indicating the requirement of
chaperone systems to deal with the accumulation of damaged proteins
[14].
Prx2 is a typical 2-cysteine (Cys) peroxiredoxin ubiquitously ex-
pressed. Prx2 has been largely investigated in erythroid cells, where it is
able to scavenge low concentration of H2O2 without inactivation due to
over-oxidation [15]. Recently, in diﬀerent cell models, Prx2 has been
also linked to chaperone activity, priming cells to better tolerate oxi-
dation [16,17]. Studies in mouse genetically lacking Prx2 (Prx2-/-) have
highlighted its protective role against LPS induced lethal shock and
acute distress syndrome (ARDS), suggesting a possible contribution of
Prx2 in inﬂammatory response [17–23]. In addition, in vitro and in vivo
model of ischemic/reperfusion stress highlighted the key role of Prx2 as
anti-oxidant system [24,25].
Here, we studied the role of Prx2 in development of pulmonary
hypertension in mice genetically lacking Prx2 (Prx2-/-), using hypoxic
stress to explore the early stage of early phase of pulmonary hy-
pertension. Our data collectively indicate that Prx2 plays a pivotal role
in the early phase of hypoxia induced pulmonary hypertension as anti-
oxidant system and chaperone. The administration of Prx2 fused to cell-
penetrating carrier PEP (cell penetrating peptide; PEP Prx2; [19]) (i)
reduces local and systemic inﬂammation; (ii) prevents vascular acti-
vation and PDGF-B up-regulation; (iii) alleviates ER stress and (i) down-
regulates autophagy activation in response to hypoxia. Thus, PEP Prx2
might represent an interesting new multimodal therapeutic option in
the early stage PAH.
2. Materials and methods
2.1. Drugs and chemicals
Details are reported in Supplemental materials and methods.
2.2. Mouse strains and design of the study
C57B6/2J mice as wildtype controls (WT) and Prx2-/- mice aged
between 4 and 6 months both male and female were used in the present
study [19,26]. The Institutional Animal Experimental Committee,
University of Verona (CIRSAL) and by the Italian Ministry of Health
approved the experimental protocols. Where indicated WT and Prx2-/-
mice were treated with 1) N-Acetyl-Cysteine (NAC) at the dosage of
100 mg/kg/d (in NaCl 0.9%, NaOH 36 mM, pH 9.4; ip) or vehicle only
for 3 weeks [19,20]; 2) PEP Prx2 (in PBS) or vehicle at the dosage of
3 mg/kg/d ip or vehicle for 4 weeks before and during hypoxia [19].
Whenever indicated, mice were exposed to hypoxia (8% oxygen for
10 h, 3 days, 7 days) (Hy) as previously described [27–29]. To collect
organs, animals were ﬁrst anesthetized with isoﬂurane, bronch-
oalveolar lavage (BAL) was collected and then mice were euthanized.
Organs were immediately removed and divided into two and either
immediately frozen in liquid nitrogen or ﬁxed in 10% formalin and
embedded in paraﬃn for histology.
2.2.1. Bronchoalveolar lavage (BAL) measurements
BAL ﬂuids were collected and cellular contents were recovered by
centrifugation and counted by microcytometry as previously reported
[27]. Percentage of neutrophils was determined on cytospin cen-
trifugation. Remaining BAL samples were centrifuged at 1500×g for
10 min at 4 °C. The supernatant ﬂuids were used for determination of
total protein content [27].
2.3. Lung molecular analysis
2.3.1. Lung histology
Multiple (at least ﬁve) three-micron whole mount sections were
obtained for each paraﬃn-embedded lung and stained with hematox-
ylin eosin, Masson's trichome, and May-Grünwald-Giemsa. α-smooth
muscle actin immunohistochemistry (IHC) on lungs was carried out as
previously reported [27,30]. Lung pathological analysis was carried out
by blinded pathologists as previously described [27,30]. Based on
previous reports (18, 38), the pathological criteria for lung histo-
pathology were as follows: i) Bronchus: Mucus: 0: no mucus; +: mucus
ﬁlling less than 50% of the area of the bronchus section; ++: mucus
ﬁlling more than 50% of the area of the bronchus section. (ii) In-
ﬂammatory inﬁltrate density: 0: less than 5 inﬂammatory cells per ﬁeld;
+: 5–30 inﬂammatory cells per ﬁeld; ++ more than 30 inﬂammatory
cells per ﬁeld. (iii) Thrombi: 0: no thrombus; + presence of a thrombus
in one ﬁeld, at magniﬁcation 250.
2.3.2. Immunoblot analysis
Frozen lung and heart from each studied group were homogenized
and lysed with iced lyses buﬀer (LB containing: 150 mM NaCl, 25 mM
bicine, 0.1% SDS, Triton 2%, EDTA 1 mM, protease inhibitor cocktail
tablets (Roche), 1 mM Na3VO4 ﬁnal concentration) then centrifuged
10 min at 4 °C at 12,000g. Proteins were quantiﬁed and analyzed by
mono-dimensional SDS polyacrylamide gel electrophoresis. Gels were
transferred to nitrocellulose membranes for immuno-blot analysis with
speciﬁc antibody. Details are reported in Supplemental materials and
methods [21,27,31–33]. Whenever indicated Prx2 dimerization was
studied in lung from PBS perfused mice containing 100 mM NEM, using
an approach similar to that reported by Kumar et al. [34].
2.3.3. RNA isolation, cDNA preparation and quantitative RT-PCR
Total RNA was extracted from tissues using Trizol reagent (Life
Technologies, Monza, Italy). Synthesis of cDNA from total RNA (1 μg)
was performed using Super Script II First Strand kits (Life
Technologies). Quantitative RT-PCR (qRT- PCR) was performed using
the SYBR-green method, following standard protocols with an Applied
Biosystems ABI PRISM 7900HT Sequence Detection system. Relative
gene expression was calculated using the 2(-ΔCt) method, where ΔCt
indicates the diﬀerences in the mean Ct between selected genes and the
internal control (GAPDH). qRT-PCR primers for each gene were de-
signed with Primer Express 2.0 (Life Technologies) (primer sequences
are reported in Table 1S) [27,30].
2.4. MDA assay
MDA was determined as previously reported [35].
2.5. Evaluation of right ventricular hypertrophy and echocardiography
measurements
Hearts were ﬁxed with 10% formaldehyde for 24 h. The right ven-
tricular (RV) free wall was separated from the left ventricular with
septum (LV+S) under dissection microscope. RV and LV + S were
separately weighed and used to calculate the ratios RV/(LV + S)/body
weight [36]. Transthoracic echocardiography was performed with a
Vevo 2100 echocardiograph (Visual Sonics, Toronto, Canada) equipped
with a 22–55 MHz transducer (MicroScan Transducers, MS500D) as
previously reported [27,37].
2.6. Statistical analysis
Data were analyzed using either t-test or the 2-way analysis of
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variance (ANOVA) for repeated measures between the mice of various
genotypes. A diﬀerence with a P value less than 0.05 was considered
signiﬁcant.
3. Results
3.1. Mice genetically lacking Prx2 show lung inﬂammation, increased
pulmonary vascular activation and extracellular-matrix remodeling
Lung histopathologic analysis showed increased peribronchial
edema without changes in the number of mucus cells in Prx2-/- mice
under normoxia compared to wildtype animals (Fig. 1A, upper panel).
The systematic study for α-smooth cells expression showed a staining in
broken line only on bronchial sections of Prx2-/- mice, suggesting an
initial pulmonary vessel muscularization (Fig. 1A, lower panel). In-
creased bronchoalveolar lavage (BAL) levels of proteins and of total
leukocytes were detected in Prx2-/- mice compared to wildtype, in-
dicating an abnormal pulmonary vascular leakage (Fig. 1SA).
In Prx2-/- mice, we observed increased active form of NF-kB and
Nrf2, two redox related transcriptional factors, compared to wildtype
animal (Fig. 1B).
This was associated with increased lung MDA levels (Fig. 1SB) and
up-regulation of the pro-inﬂammatory cytokines IL-6, IL-1b and IL10
that are known targets of NF-kB (Fig. 1C). We conﬁrmed the increased
expression of IL-6 by immunoblot analysis in lung from Prx2-/- mice
compared to wildtype animals (Fig. 1D). The activation of Nrf2 in the
absence of Prx2 was supported by the up-regulation of Nrf2 related
systems such as HO-1, a vascular and lung cytoprotector, and SOD-1, a
potent anti-oxidant enzyme supports (Fig. 1D) [38]. We also observed
higher levels of (i) endothelin-1 (ET-1), the most potent vasoconstric-
tive and broncho-constrictive cytokine [30]; (ii) VCAM-1, a marker of
vascular endothelial activation [27]; and (iii) PDGF-B, a known factor
involved in lung extra-cellular matrix remodeling [39] (Fig. 1D).
These data link the absence of Prx2 with persistent lung in-
ﬂammation, endothelial vascular activation, and extracellular matrix
remodeling.
Fig. 1. The absence of Prx2 promotes lung inﬂammation, increased pulmonary vascular activation and extra-matrix remodeling markers. A. Comparison of Prx2-/- with WT
mice shows an increased peribronchial edema in Prx2-/- mice (upper panel Hematoxylin Eosin ×250) and deposits of alpha actin in vascular walls in Prx2-/- mice (lower panel
Immunohistochemistry using anti alpha actin antibody × 600). B. Immunoblot analysis with speciﬁc antibodies against phospho-NF-kB (P-NF-kB), NF-kB, phospho-Nrf2 (P-Nrf2) and
Nrf2 of lung from wildtype (WT) and Prx2-/- mice under normoxic condition. One representative gel from six with similar results is presented. Right panel. Densitometric analysis (DU:
Density Units) of immunoblots is shown as means± SD (n= 6); *p<0.05 compared to wildtype. C. IL-6, IL-1b, IL-10 mRNA levels in lung tissues (normalized to GADPH) from WT and
Prx2-/- mice. * p< 0.05 (WT vs Prx2-/-). Each sample (WT; Prx2-/-) is a pool from 5 mice. Representative of three independent experiments. D. Immunoblot analysis with speciﬁc
antibodies against IL-6, heme-oxygenase 1 (HO-1), endothelin-1 (ET-1), superoxide dismutase (SOD-1), vascular cell adhesion molecule-1 (VCAM-1), platelet derived growth factor-B
(PDGF-B) and peroxiredoxin-2 (Prx2) of lung from wildtype (WT) and Prx2-/- mice under normoxic condition. One representative gel from six with similar results is presented. Right
panel. Relative quantiﬁcation of immunoreactivity (DU: Density Units) of IL-6, HO-1, SOD1, ET-1, VCAM1, PDGF-B and Prx2 of lung from wildtype (WT) and Prx2-/- mice under
normoxic condition. Data are shown as means± SD (n = 6); *p< 0.05 compared to wildtype.
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3.2. Prolonged hypoxia promotes the development of early stage pulmonary
hypertension in Prx2-/- mice
Based on our previous report, showing the development of early
stage PAH in a mouse model for sickle cell disease but not in wildtype
mice [36], we exposed both mouse strains to hypoxia (Hy) 8% oxygen
for 7 days. As shown in Fig. 2A, hypoxia induced sparse inﬂammatory
cell inﬁltrate with some peribronchial edema in Prx2-/- mice. On the
bronchial epithelium there was no signiﬁcant change in the number of
mucus cells in both mouse strains. On vascular sections, no thrombus
was found in any of the mouse groups. The systematic study for α-actin
deposition revealed the presence of almost linear staining around
bronchial and vascular sections in Prx2-/- mice (Fig. 2A, lower panel).
While, α-actin depositions were sparse in hypoxic wildtype mice.
We evaluated the presence of RV hypertrophy in both mouse strains
exposed to 7days hypoxia. In Prx2-/- mice, we observed a slight but
signiﬁcant increase in RV/(LV + S) ratio (normoxia: 0.21±0.03 vs
hypoxia 0.34±0.05; n = 6, P<0.05), whereas no changes were ob-
served in wildtype mice in agreement with our previous report [36].
This was associated with a signiﬁcant increase in mitral valve decel-
eration time and a reduction in pulmonary acceleration time/ ejection
time ratio (Fig. 2B), indicating early diastolic dysfunction and increased
right ventricular systolic pressure in Prx2-/- mice. In addition, we found
hypoxia induced increased expression of SOD-1 in heart from both
mouse strains, but to a higher extent in Prx2-/- mice (Fig. 1SD). Hypoxia
induced up-regulation of (i) VCAM-1 and ICAM-1; and (ii) atrial na-
triuretic peptide (ANP) was also observed in both mouse strains
(Fig. 1SD).
Our ﬁndings are consistent with the development of early stage of
PAH promoted by severe oxidation and ampliﬁed inﬂammatory re-
sponse in Prx2-/- mice exposed to 7-days hypoxia.
3.3. Prx2 plays an important role as cytoprotective system against hypoxia
induced PAH
In order to follow-up the generation of PAH in Prx2-/- mice, we
studied both mouse strains at diﬀerent time intervals between 0 to 7-
days hypoxia to identify the optimal window-time to analyze
Fig. 2. In Prx2-/- mice, hypoxia induces early stage pulmonary hypertension and is associated with activation of redox-related transcriptional factors. A. Comparison of Prx2-/-
with WT mice shows a sparse inﬂammatory inﬁltrate and an increased peribronchial edema in Prx2-/- mice (upper panel Hematoxylin Eosin ×250) and deposits of alpha actin in vascular
walls in Prx2-/- mice (lower panel Immunohistochemistry using anti alpha actin antibody × 600). B. Representative images of mitral inﬂow pattern recorded by Doppler echo imaging in
wildtype (WT) and Prx2-/- mice under hypoxia as in Fig. 1A. Lower panels. Average mitral valve deceleration time (left panel) and pulmonary acceleration time (PAT) to ejection time
(ET) ratio (right panel). *p<0.05 and **p< 0.01 WT vs Prx2-/- mice; #p<0.05 and ##p<0.01 hypoxia vs basal by one-way ANOVA followed by Newman-Keuls Multiple Comparison
test. The black dashed lines have been added to the graph to favor visual comparison between the white bars vs the black bars. C. Immunoblot analysis with speciﬁc antibodies against
peroxiredoxin-2 (Prx2) and thioredoxin-reductase 1 (Trdx) of lung wildtype (WT) and Prx2-/- mice under normoxia (N) exposed to hypoxia) for 10 h (10 h), 3 days (3D), 7 days (7D). One
representative gel from six with similar results is presented. Densitometric analysis of immunoblots is shown in Fig. 2SA. D. Immunoblot analysis with speciﬁc antibodies against phospho-
NF-kB (P-NF-kB), NF-kB, phospho-Nrf2 (P-Nrf2) and Nrf2 of lung wildtype (WT) and Prx2-/- mice under normoxia (N) and exposed to hypoxia (Hy) for 10 h (10 h), 3 days (3D), 7 days
(7D). One representative gel from six with similar results is presented. Densitometric analysis of immunoblots is shown in Fig. 2SB.
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mechanism(s) involved in development of PAH. BAL protein and leu-
kocyte count were signiﬁcantly increased in Prx2-/- mice during hy-
poxia at 10 h, 3 days and 7 days compared to wildtype animals (data
not shown).
Hypoxia markedly increased Prx2 expression in lung from wildtype
mice at 10 h, 3 days and 7 days of exposure (Fig. 2C; Fig. 2SA). This was
associated with time dependent increased expression of thioredoxin-
reductase, a Prx2 repairing system (Trdx; Fig. 2C; Fig. 2SA). The
modulation of Trdx expression during hypoxia even in the absence of
Prx2, may be possible related to the fact that Trdx is part of diﬀerent
NADPH-dependent pathways [19,40].
In Prx2-/- mice exposed to hypoxia, we observed a rapid and sus-
tained activation of Nrf2 in response to hypoxia, while there was a
reduction in activation of NF-kB (Fig. 2D, 2SB). Otherwise, wildtype
mice showed an early response of Nrf2 at 10 and 3-h hypoxia, partially
overlapping the activation of NF-kB observed at 3 and 7 days hypoxia
(Figs. 2D, 2SB). These data suggest that Nrf2 might be a precocious
back-up mechanism in response to hypoxia, which is early activated in
both mouse strains, but to higher extent in mice genetically lacking
Prx2.
Since pro-inﬂammatory cytokines are modulated by oxidation and
participates to the development of PAH [3,41,42], we evaluated IL1b
and IL6 expression in lung from both mouse strains during hypoxia. In
Prx2-/- mice, IL-1b mRNA levels were signiﬁcantly increased at 3 days
of hypoxia compared to wildtype animals, which displayed increased
IL-1b expression only at 7-days hypoxia (Fig. 3A). In Prx2-/- mice, lung
IL-6 mRNA expression was signiﬁcantly upregulated at 3 days of hy-
poxia followed by a decreased at 7 days of hypoxia to levels still higher
than those observed in wildtype mice (Fig. 3B). These data support an
earlier and ampliﬁed inﬂammatory response in Prx2-/- mice in response
to hypoxia compared to wildtype animals.
We then evaluated markers of pulmonary vascular remodeling (ET-
1, PDGF-B, ANP) and vascular endothelial activation (VCAM-1 and
ICAM-1). As shown in Fig. 3C, ET-1 expression was increased in both
mouse strains but to a higher extent in Prx2-/- mice compared to
wildtype; while PDGF-B levels increased earlier, reaching higher and
constant levels in Prx2-/- mice compared to wildtype during hypoxia.
VCAM-1 and ICAM-1 expression was similarly increased in both mouse
strains at 7 days hypoxia (Fig. 3D). Whereas, ANP levels were higher in
Prx2-/- mice than in wildtype animals exposed to prolonged hypoxia
(Fig. 3D).
Collectively, these data indicate that the absence of Prx2 accelerates
vascular activation and extra-cellular matrix remodeling, amplifying
inﬂammatory response and oxidation during hypoxia.
3.4. The absence of Prx2 is associated with endoplasmic reticulum (ER)
stress and up-regulation of ATF6
Studies in diﬀerent models of PAH have shown that hypoxia and/or
PDGF-B and /or ET-1 induce severe proteins damage, which promotes
endoplasmic reticulum stress (ER), triggering unfolded protein response
(UPR) system [10,11,13,43]. When the accumulation of damaged pro-
teins exceeds the ER capacity, ER stress leads to activation of autophagy
as adaptive mechanism to clear accumulated misfolded/unfolded pro-
teins [11,44]. UPR system is characterized by 3 branches: IRE, PERK
and ATF6, this latter has been reported to be mainly involved in PAH
[12,45]. As shown in Fig. 4A, ATF6, Chop and sXbp1 were up-regulated
in lung from Prx2-/- mice under normoxia compared to wildtype ani-
mals. Whereas, GADD34 was downregulated in Prx2-/- mice compared
to wildtype animals (Fig. 4A). In response to hypoxia, we observed
dynamic changes of the main UPR systems: (i) ATF6; (ii) GADD34 and
Chop, related to PERK and Xbp1, a component of IRE branch [10]. As
shown in Fig. 4B, increased mRNA levels of both Chop and Xbp1 were
observed at 10 h in Prx2-/- mice, while GADD34 was still signiﬁcantly
increased at 3-days hypoxia compared to normoxic Prx2-/- animals. In
chronically exposed Prx2-/- mice, ATF6 and sXbp1 mRNA levels were
again higher than in normoxia Prx2-/- animals (Fig. 4B). Wildtype an-
imals show an early signs of ER stress with up-regulation of ATF6 and
Xbp1 at 10-h hypoxia, with no major change in chronic hypoxia
(Fig. 4B). It is of note that in lung from wildtype mice, we found Prx2
organized in multimers, possible reﬂecting the acquisition of chaperone
like function (data not shown) [31,46,47].
These data indicate that the absence of Prx2 triggers ER stress
during hypoxia, contributing to the early appearance of PAH in Prx2-/-
mice.
3.5. PEP Prx2 treatment rescues prolonged hypoxia induced heart and lung
inﬂammatory vasculopathy and prevents ER stress
To address the question whether Prx2 plays a role in lung chronic
inﬂammatory disease, we ﬁrstly evaluated the impact of recombinant
fusion protein PEP Prx2 (1.5 mg/kg/day ip; 3 weeks) to both mouse
strains under room air condition. In normoxic Prx2-/- mice, PEP Prx2
treatment (i) prevented Nrf2 and NF-kB activation (Fig. 3SA); (ii) re-
duced HO-1 protein expression (Fig. 3SB); and (iii) decreased the levels
of ET-1, VCAM-1 and PDGF-B (Fig. 3SB). No major changes were ob-
served in wildtype animals (Fig. 3SA, 3SB). In order to evaluate whe-
ther the eﬀects of PEP Prx2 treatment were speciﬁc of Prx2 or related to
a general anti-oxidant eﬀect, we treated both mouse strains with NAC
(100 mg/kg/day for 3 weeks), a known anti-oxidant agent previously
used in other in vitro and in vivomodels of PAH [6,48]. No changes were
present in the levels of Nfr2 and NF-kB activation in Prx2-/- mice treated
with NAC, suggesting that the eﬀects of PEP Prx2 are peculiar of Prx2
and not only related to its general antioxidant eﬀects (data not shown).
In Prx2-/- mice exposed to 7 days hypoxia, PEP Prx2 treatment
signiﬁcantly reduced the hypoxia mediated diastolic dysfunction and
ameliorated RVSP, as suggested by the increased in PAT/ET ratio
(Fig. 4C, 4SA). In agreement, in heart from PEP Prx2 treated Prx2-/-
mice exposed to 7 days hypoxia, we found a reduction of ANP ex-
pression as well as of markers of vascular endothelial activation
(Fig. 4D). This was associated with a decrease in levels of SOD-1 and in
oxidation of proteins from heart of hypoxic Prx2-/- mice treated with
PEP Prx2 (Fig. 4SB). We found similar evidences of the beneﬁcial eﬀects
of PEP Prx2 on lung from Prx2-/- mice exposed to prolonged hypoxia. As
shown in Fig. 5A, PEP Prx2 promoted a signiﬁcant reduction in chronic
hypoxia induced increase of ANP, VCAM-1, ICAM-1 and PDGF-B levels
compared to vehicle treated Prx2-/- animals. In addition, PEP Prx2 de-
creased the hypoxia induced ATF6 expression, suggesting a possible
role of Prx2 as chaperone in agreement with the reduced expression of
classic chaperone HSP70 and 90 (Fig. 5B).
To better understand the role of Prx2 in development of PAH, we
chose to further study Prx2-/- mice at day 3 of hypoxia. This represents
the turning point in the imbalance between oxidation/anti-oxidant
activities and the activation of cellular defense mechanisms against
cytotoxic eﬀects of accumulation of damage proteins. Indeed, we found
a signiﬁcant increase in the amount of Prx2 dimers in lung from wild-
type after 3 days hypoxia compared to normoxic wildtype animals
(Fig. 4SC), supporting the role of Prx2 as H2O2 sensor generated during
hypoxia as previously shown in other models [34,49].
3.6. In Prx2-/- mice, PEP Prx2 prevents the hypoxia induced oxidative stress
and reduces inﬂammatory vascular activation and extracellular matrix
remodeling
PEP Prx2 administration prevented the hypoxia induced increased
in BAL protein and leukocyte content in both mouse strains (Fig. 4SD).
This was associated with a marked reduction in protein oxidation state
in both mouse strains exposed to 3 days hypoxia and treated with PEP
Prx2, supporting the local anti-oxidant eﬀect of exogenous PEP Prx2
treatment during hypoxia stress (Fig. 5C). In agreement, we found that
PEP Prx2 administration prevented the hypoxia induced Nrf2 and NF-
kB activation in both mouse strains (Fig. 5D, 5SA). This was paralleled
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by the reduction in HO-1, IL-6, ET-1, VCAM-1 and PDGF-B (Fig. 6A).
These data suggest that PEP Prx2 treatment during hypoxia is able
to (i) decrease local pulmonary inﬂammation and oxidation, (ii) reduce
systemic inﬂammatory response; (iii) beneﬁcially aﬀect hypoxia ab-
normalities in pulmonary vascular leakage; and (iv) prevent hypoxia
activation of redox-sensitive transcriptional factors Nrf2 and NF-kB.
3.7. PEP Prx2 alleviates ER stress and down-regulates autophagy in Prx2-/-
mice exposed to hypoxia
As shown in Fig. 6B, PEP Prx2 signiﬁcantly down-regulated G-
ADD34 in lung from Prx2-/- mice compared to vehicle treated animals.
This was associated with a marked decrease in HSP70 and 90 expres-
sion in lung from both mouse strains exposed to 3 days hypoxia and
treated with PEP Prx2 (Fig. 6C). This is agreement with previous reports
on preventing PAH development by blocking ER stress with exogenous
chemical chaperones [12].
Since a link between ER stress and activation of autophagy has been
proposed to deal the accumulation of damaged proteins [10,44], we
evaluated key elements of autophagy machinery and the eﬀects of PEP
Prx2 treatment in both mouse strains at 3 days hypoxia. Based on re-
vision of the literature, we chose to analyze the expression of (i) au-
tophagy related proteins ULk1 that is required for initiation of autop-
hagy; (ii) LC3 I/II, a coordinator of phagosomal membranes and (iii)
p62, a key cargo protein and component of inclusion bodies; and (iv)
pro-caspase 3/caspase 3, involved in digestion of damaged proteins
[9,50–52]. As shown in Fig. 7A, normoxic Prx2-/- mice showed in-
creased LC3-II formation associated with increased expression of Ulk1
and p62 compared to wildtype mice. This was associated with higher
expression of pro-caspase 3/caspase 3, indicating an activation of au-
tophagy to clear intracellular oxidative damaged proteins in Prx2-/-
mice. In both mouse strains, hypoxia markedly activated autophagy as
supported by increased LC3I/II expression, consumption of Ulk1 and
reduction of p62, suggesting a clearance of p62 positive inclusion
Fig. 3. In Prx2-/- mice, hypoxia is associated with ampliﬁed inﬂammatory response, vascular activation and increased expression of PDGF-B, a marker of extracellular matrix
remodeling. A-B. IL-1b (A) and IL-6 (B) mRNA levels in lung tissues (normalized to GADPH) wildtype (WT) and Prx2-/- mice under normoxia (N) and exposed to hypoxia for 10 h (10 h),
3 days (3D), 7 days (7D). *p< 0.05 compared to wildtype; ^ p value< 0.05 compared to normoxic mice. Each sample is a pool from 5 mice. Representative of three independent
experiments. C. Upper panel. Immunoblot analysis with speciﬁc antibodies against endothelin-1 (ET-1) and platelet derived growth factor-B (PDGF-B) of lung from wildtype (WT) and
Prx2-/- mice under normoxia (N) and exposed to hypoxia for 10 h (10 h), 3 days (3D), 7 days (7D). One representative gel from six with similar results is presented. Lower panel. Relative
quantiﬁcation of immunoreactivity (DU: Density Units) of ET-1 and PDGF-B in lung from wildtype (WT) and Prx2-/- mice under normoxia (N) and exposed to hypoxia for 10 h (10 h), 3
days (3D), 7 days (7D). Data are shown as means± SD (n= 6). *p<0.05 compared to wildtype; ^ p< 0.05 compared to normoxic mice. The grey area highlights the changes in the ET-1
and PDGF-B expression in the mouse strains at 3 days hypoxia. D. Upper panel. Immunoblot analysis with speciﬁc antibodies against atrial natriuretic peptide (ANP), vascular adhesion
molecule -1 (VCAM-1) and intracellular adhesion-molecule- 1 (ICAM-1) of lung from wildtype (WT) and Prx2-/- mice under normoxia (lane 1 and 2) and exposed to 7 days (7D) hypoxia.
One representative gel from six with similar results is presented. Lower panel. Relative quantiﬁcation (DU: Density Units) of immunoreactivity of ANP, VCAM-1, ICAM-1 in lung from
wildtype (WT) and Prx2-/- mice under normoxia and exposed to 7 days (7D) hypoxia. Data are shown as means± SD (n = 6); *p< 0.05 compared to wildtype; ^ p< 0.05 compared to
normoxic mice.
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bodies containing damaged proteins (Fig. 7A). It is of note that the pro-
caspase/caspase 3 ratio was also increased in both mouse models ex-
posed to hypoxia, but to higher extent in Prx2-/- mice compared to
wildtype (Fig. 7A).
As a proof of concept that Prx2 is important in the crossroad be-
tween hypoxia induced oxidation and autophagy, we evaluated the
eﬀects of PEP Prx2 treatment on autophagy in mice exposed to 3 days
hypoxia. As shown in Fig. 7A, PEP Prx2 administration rescued the
hypoxia induced activation of autophagy. These data indicate that Prx2
acts as multimodal cytoprotective system and is important to prevent
the development of PAH.
4. Discussion
Here, we ﬁrstly show the novel role of Prx2 as lung multimodal
cytoprotector against hypoxia induced PAH. Our data also indicate that
Prx2 is required in management of the physiologic oxidation in lung
under room air condition. In fact, normoxic Prx2-/- mice show we lung
chronic inﬂammatory vasculopathy and vascular dysfunction, asso-
ciated with activation of extracellular matrix remodeling. This is in
agreement with previous studies in mouse models genetically lacking
other anti-oxidant systems such as SOD-1, which show increased sus-
ceptibility to both acute and chronic lung injury [53–55].
Fig. 4. Hypoxia induces ER stress in Prx2-/- mice and PEP Prx2 administration prevents the hypoxia induced diastolic dysfunction with reduction of inﬂammatory vascu-
lopathy. A-B. ATF6, CHOP, GADD34, sXBP1 mRNA levels in lung tissues wildtype (WT) and Prx2-/- mice under normoxia (N) *p< 0.05 compared to wildtype. Each sample is a pool from
5 mice. Representative of three independent experiments (A). ATF6, CHOP, GADD34, sXBP1 mRNA levels in lung tissues (normalized to GADPH) wildtype (WT) and Prx2-/- mice exposed
to hypoxia for 10 h (10 h), 3 days (3D), 7 days (7D). Each sample is a pool from 5 mice. (B) ATF6 *p<0.05 for WT mice 10 h vs 3D; 10 h vs 7D. ATF6 *p< 0.05 for Prx2-/- mice 10 h vs
3D; ^ p< 0.05 for WT mice 7D vs Prx2-/- mice 7D. CHOP *p<0.05 for WT mice 10 h vs 3D; 10 h vs 7D. CHOP *p<0.05 for Prx2-/- mice 10 h vs 3D; 10 h vs 7D; ^ p< 0.05 for WT mice
10 h vs Prx2-/- mice 10 h. GADD34 *p<0.05 for WT mice 10 h vs 3D; 10 h vs 7D. GADD34 *p<0.05 for Prx2-/- mice 10 h vs 3D. sXbp1 *p< 0.05 for WT mice 10 h vs 3D; 10 h vs 7D. ^
p<0.05 for WT mice 7D vs Prx2-/- mice 3D and 7D. sXbp1 *p< 0.05 for Prx2-/- mice 10 h vs 3D. ^ p< 0.05 for WT mice 7D vs Prx2-/- mice 7D. C. Average mitral valve deceleration time
(left panel) and pulmonary acceleration time (PAT) to ejection time (ET) ratio (right panel); *p< 0.05 vehicle treated Prx2-/- mice vs PEP Prx2 treated Prx2-/- mice; by one-way ANOVA
followed by Newman-Keuls Multiple Comparison test. The black dashed lines have been added to the graph to favor visual comparison between the white bars vs the black bars.
Representative images of mitral inﬂow pattern recorded by Doppler echo imaging in Prx2-/- mice treated with PEP Prx2 are shown in Fig. 4SA. D. Immunoblot analysis with speciﬁc
antibodies against atrial natriuretic peptide (ANP), vascular adhesion molecule -1 (VCAM-1), intracellular adhesion-molecule- 1 (ICAM-1) and superoxide dismutase-1 (SOD-1) of heart
from Prx2-/- mice under normoxia (lane 1) and exposed to 7 days (7D) hypoxia treated with either vehicle or PEP Prx2. One representative gel from six with similar results is presented;
GAPDH was used as protein loading control. Right panel. Relative quantiﬁcation of immunoreactivity (DU: Density Units) of ANP, VCAM-1, ICAM-1, SOD1 of heart from Prx2-/- mice
under normoxia and exposed to 7 days (7D) hypoxia treated with either vehicle or PEP Prx2. Data are presented as means± SD (n = 6); ^p< 0.05 compared to Prx2-/- normoxic mice; °
p<005 compared to vehicle treated mice.
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Prx2-/- mice exposed to prolonged hypoxia developed signs of PAH,
combined with inﬂammatory vasculopathy, sustained by high ET-1
expression and increased PDGF-B levels, as marker of extracellular
matrix remodeling. Both molecules have been reported to accelerate the
development of hypoxia induce PAH [30,39]. The increase ANP lung
and heart expression indicates an attempt of endogenous system to
induce pulmonary vaso-relaxation and to modulate lung and heart
vascular remodeling in response to hypoxia [56,57]. This was co-
ordinated by hypoxia induced activation of acute phase related tran-
scriptional factors: Nrf2 and NF-kB in both mouse strains. The early and
higher activation of Nrf2 in Prx2-/- mice compared to wildtype animals,
supports the role of Nrf2 as back-up mechanism against severe oxida-
tion in mice genetically lacking Prx2 [19]. Whereas, NF-kB seemed to
be more important in prolonged hypoxia for wildtype mice compared to
Prx2-/- animals. The rescue experiments with PEP Prx2 corroborate the
importance of Prx2 in the functional cascade activated in response to
hypoxia.
In this scenario, the absence of Prx2 favors ER stress with the ac-
tivation of autophagy, as important mechanisms to deal with the
accumulation of cytotoxic damaged proteins triggered by hypoxia and
oxidation [10,44]. ER stress activates the UPR system, which is divided
into three branches: ATF6, PERK and IRE1 [10,13]. In Prx2-/- mice,
ATF6 was up-regulated in lung from animals under normoxia and after
prolonged hypoxia. Whereas, GADD34, part of PERK branch, was early
up-regulated at 3 days hypoxia in Prx2-/- mice. This indicate that the
absence of Prx2 favors ER stress most likely due to a reduction of en-
dogenous chaperone power beside the increased expression of classic
heat shock proteins such as HSP70 and 90 in response to hypoxia. PEP
Prx2 alleviated ER stress and prevented the hypoxia induced up-reg-
ulation of UPR system, in agreement with previous report on exogenous
chemical chaperones, reducing ER stress and preventing the develop-
ment of PAH [12,13]. It is of interest to note that previous reports have
shown that PDGF-B and/or ET- activates UPR [13,43]. In our model,
the absence of Prx2 resulted in high levels of PDGF-B and ET1 that
potentiate the hypoxia induced activation of UPR system. The rescue
experiments with PEP Prx2 corroborate the pivotal role of Prx2 in lung
homeostasis.
The behavior of defensive autophagy in Prx2-/- mice exposed to
Fig. 5. PEP Prx2 administration prevents lung vascular remodeling and alleviates ER stress induced by prolonged hypoxia. A. Immunoblot analysis with speciﬁc antibodies
against atrial natriuretic peptide (ANP), vascular adhesion molecule -1 (VCAM-1), intracellular adhesion-molecule- 1 (ICAM-1) and PDGF-B of lung from Prx2-/- mice under normoxia
(lane 1) and exposed to 7 days (7D) hypoxia treated with either vehicle or PEP Prx2. One representative gel from six with similar results is presented; GAPDH was used as protein loading
control. Right panel. Relative quantiﬁcation of immunoreactivity (DU: Density Units) of ANP, VCAM-1, ICAM-1 and PDGF-B in lung from Prx2-/- mice under normoxia (lane 1) and
exposed to 7 days (7D) hypoxia treated with either vehicle or PEP Prx2. Data are shown as means± SD (n = 6); ^ p< 0.05 compared to Prx2-/- normoxic mice; ° p< 0.05 compared to
Prx2-/- treated with vehicle. B. Immunoblot analysis with speciﬁc antibodies against activating transcriptional factor-6 (ATF6), heat shock protein 70 (HSP70) and heat shock protein 90
(HSP90) of lung from Prx2-/- mice under normoxia (lane 1) and exposed to 7 days (7D) hypoxia treated with either vehicle or PEP Prx2. One representative gel from six with similar results
is presented; GAPDH was used as protein loading control. Right panel. Relative quantiﬁcation of immunoreactivity (DU: Density Units) of ATF6, HSP70 and HSP90. Data are shown as
means± SD (n = 6); ^ p<0.05 compared to Prx2-/- normoxic mice; ° p<0.05 compared to Prx2-/- treated with vehicle. C. The carbonylated proteins (1 μg) were detected by treating
with DNPH and blotted with anti-DNP antibody. Right panel. Quantiﬁcation of band area was performed by densitometry and expressed as % of WT. The data are presented as
means± SD of at least three independent experiments *p<0.05 compared to WT; ° p< 0.05 compared to vehicle treated mice (n= 3). D. Immunoblot analysis with speciﬁc antibodies
against phospho-NF-kB (P-NF-kB), NF-kB, phospho-Nrf2 (P-Nrf2) and Nrf2 of lung from wildtype (WT) and Prx2-/- mice under normoxic condition treated with either vehicle or
penetrating peptide fusion protein peroxiredoxin-2 (PEP Prx2). One representative gel from six with similar results is presented. Densitometric analysis of immunoblots is shown in
Fig. 5SA.
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hypoxia is strongly linked to ER stress in the absence of Prx2. Treatment
with PEP Prx2 reduced ER stress and switched-oﬀ autophagy as sup-
ported by the reduction in LC3II and accumulation of p62 (Fig. 6A).
This was parallel by a decrease of hypoxia induced HSP70 and 90 ex-
pression and down-regulation of GADD34 and ATF6 levels in PEP Prx2
treated Prx2-/- mice exposed respectively to 3 and 7 days hypoxia.
Collectively, our data indicate that PEP Prx2 has a multimodal ac-
tion targeting: (i) the inﬂammatory response; (ii) vascular and extra-
cellular matrix remodeling, (iii) ER stress and autophagy (Fig. 7B). The
correction of the imbalance between oxidation and anti-oxidant sys-
tems combined with a chaperone like function exerted by Prx2 might
interrupt the vicious circle, established between oxidation-chronic in-
ﬂammation with ER stress and activation of autophagy towards the
generation of PAH (Fig. 7B).
In conclusion, we have ﬁrstly highlighted the novel pivotal role of
Prx2 in preventing PAH induced by hypoxia. The high bio-complexity
of PAH requires multimodal therapeutic approaches, which simulta-
neously act on diﬀerent targets involved in its pathogenesis. Our data
collectively support a rationale for considering Prx2 as novel
therapeutic option in treatment of the early phase of PAH.
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Fig. 6. PEP Prx2 administration reduces ER stress and prevents chaperone expression in the early phase of hypoxia. A. Immunoblot analysis with speciﬁc antibodies against IL-6,
endothelin-1 (ET-1), vascular cell adhesion molecule-1 (VCAM-1), platelet derived growth factor-B (PDGF-B) of lung from wildtype (WT) and Prx2-/- mice under normoxic condition
treated (lane 1–2) or exposed to hypoxia (3D) and treated with either vehicle or penetrating peptide fusion protein peroxiredoxin-2 (PEP Prx2). One representative gel from six with
similar results is presented. GAPDH was used as loading control. Right panel. Relative quantiﬁcation of immunoreactivity (DU: Density Units) of IL-6, ET-1, VCAM-1 and PDGF-B. Data
are shown as means± SD (n= 6). *p< 0.05 compared to wildtype; ^p<0.05 compared to normoxic mice; °p< 005 compared to vehicle treated mice. B. GADD34 levels in lung tissues
(normalized to GADPH) wildtype (WT) and Prx2-/- mice treated with either vehicle or penetrating peptide fusion protein peroxiredoxin-2 (PEP Prx2) exposed to hypoxia for 3D *p<0.05
compared to wildtype. Each sample is a pool from 5 mice. Representative of three independent experiments. C. Immunoblot analysis with speciﬁc antibodies against heat shock protein-
70 (HSP70) and -90 (HSP90) of lung from wildtype (WT) and Prx2-/- mice under normoxic condition treated (lane 1–2) or exposed to hypoxia (3D) and treated with either vehicle or
penetrating peptide fusion protein peroxiredoxin-2 (PEP Prx2). One representative gel from six with similar results is presented. GAPDH was used as loading control. Right panel. C.
Relative quantiﬁcation of immunoreactivity (DU: Density Units) of HSP70 and HSP 90. Data are shown as means± SD (n = 6); ^p< 0.05 compared to normoxic mice; °p<005
compared to vehicle treated mice.
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